



an Open Access Journal by MDPI

State-of-the-Art Cancer Biology and Therapeutics in Italy

Guest Editors:

Dr. Luca Pacini

Department of Medico-Surgical
Sciences and Biotechnologies,
University of Rome "Sapienza",
Roma, Italy

Dr. Umberto Malapelle

Department of Public Health,
University of Naples Federico II,
Naples, Italy

Deadline for manuscript
submissions:
closed (29 February 2024)

Message from the Guest Editors

Cancer still represents one of the leading causes of death in the world and in Italy, there have been many advances in the treatment and care of cancer patients; new molecular targeted therapies and new knowledge in the molecular field represent an important step. Understanding the basic biological processes, new biomarkers and their clinical characteristics will be fundamental for new therapies based on evaluating the individual response to treatments. Together, these data will open the way for more personalized medicine.

This call for papers aims to collect high quality documents on the research areas in tumor diseases in Italy, with particular attention to studies on biological heterogeneity, their impact in the clinic, studies on molecular biology and studies on new molecular pathways. The use of multidisciplinary approaches is essential for the success of this field; therefore, contributions including interdisciplinary studies (epidemiology, genetics, molecular biology, cell biology, immunology and pharmacology) are strongly encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI